NCT00170950 - Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension | Biotech Hunter

Enrollment

11,506

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

January 31, 2008

Study Completion Date

May 31, 2008

Conditions

Hypertension

Interventions

DRUG

Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1

Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.

DRUG

Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2

Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.

DRUG

Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.

DRUG

Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1

Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.

DRUG

Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2

Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.

DRUG

Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.

Trial Locations (5)

07936

Novartis Pharmaceuticals, East Hanover

Unknown

sites in Denmark, Denmark

sites in Finland, Finland

sites in Norway, Norway

sites in Sweden, Sweden